Holen Sie sich die Stockscreener-App
177.04
0.87%
1.435
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$175.61
Offen:
$178.24
24-Stunden-Volumen:
360.24K
Relative Volume:
0.27
Marktkapitalisierung:
$25.98B
Einnahmen:
$9.53B
Nettoeinkommen (Verlust:
$1.29B
KGV:
20.11
EPS:
8.8057
Netto-Cashflow:
$1.97B
1W Leistung:
-3.61%
1M Leistung:
-4.18%
6M Leistung:
+17.33%
1J Leistung:
+55.32%
1-Tages-Spanne:
$176.35
$179.81
1-Wochen-Bereich:
$168.64
$181.98
52-Wochen-Spanne:
$110.03
$202.41
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
177.05 | 25.77B | 9.53B | 1.29B | 1.97B | 8.8057 |
LLY
Lilly Eli Co
|
957.76 | 831.80B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
239.44 | 574.24B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
211.03 | 365.02B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
204.54 | 311.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
122.47 | 294.91B | 64.93B | 18.26B | 12.36B | 7.2751 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-09 | Bestätigt | H.C. Wainwright | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2025-11-06 | Hochstufung | Stifel | Hold → Buy |
| 2025-09-25 | Eingeleitet | Jefferies | Buy |
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Biogen, Investors Reach Deal In Alzheimer's Drug Litigation - Law360
Biogen (NASDAQ: APLS) readies tender offer for Apellis under March 31, 2026 deal - Stock Titan
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Why Biogen (BIIB) could beat earnings estimates again - MSN
Why Biogen (BIIB) Could Beat Earnings Estimates Again - Yahoo Finance
Alloy Therapeutics and Biogen Announce Multi-Target Collaboration - National Today
What Is Driving Biogen’s Recent Drop and What Comes Next - Trefis
Biogen (BIIB) Partners With Alloy Therapeutics on Antisense Drug Platform - Blockonomi
Biogen (BIIB) Stock Signs ASO Platform Deal With Alloy Therapeutics - CoinCentral
Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward - Benzinga
RBC Capital Adjusts Biogen Price Target to $213 From $233, Maintains Outperform Rating - marketscreener.com
Alloy Therapeutics Partners with Biogen on Multi-Target Collaboration - National Today
Avoiding Lag: Real-Time Signals in (BIIB) Movement - Stock Traders Daily
Biogen’s Apellis Deal And High Dose SPINRAZA Shift Growth Outlook - simplywall.st
Alloy Therapeutics enters into multi-target collaboration and license agreement with Biogen for use of Alloy's Anticlastic™ ASO platform - marketscreener.com
Alloy Therapeutics Enters Into Multi-Target Collaboration And License Agreement With Biogen For Use Of Alloy’S Anticlastic™ Aso Platform - TradingView
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform - Business Wire
Why Biogen (BIIB) May Surpass Earnings Projections Once More - Bitget
Why Biogen Stock Got Mashed on Monday - finance.yahoo.com
Biogen (NASDAQ: APLS) files Form 3 on Apellis voting group status - Stock Titan
Biogen Discloses Tender Offer at Apellis with 14.2% Stake - TradingView
[SCHEDULE 13D] Apellis Pharmaceuticals, Inc. Major Shareholder Acquisition (>5%) - Stock Titan
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology - The Chronicle-Journal
Biogen : to Report First Quarter 2026 Financial Results April 29, 2026 - marketscreener.com
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.
Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease (NASDAQ:BIIB) - Seeking Alpha
Biogen Paid a 140% Premium for Apellis. Was the $5.6B Deal Worth It? - TIKR.com
Biogen Expects to Take $0.19 per Share Charge in Q1 - marketscreener.com
Biogen Inc. 8-K SEC Filing Details for April 6, 2026: Company Information, Stock, and Compliance Overview - Minichart
Biogen expects $34 million charge for research and development expenses By Investing.com - Investing.com India
Biogen expects $34 million charge for research and development expenses - Investing.com
BiogenExpects Q1 2026 GAAP and non-GAAP EPS impact of $0.19 from chargeSEC filing - marketscreener.com
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get - Benzinga
Biogen (NASDAQ: BIIB) projects $34M Q1 2026 in-process R&D expense - stocktitan.net
Biogen Inc. (BIIB) stock price, news, quote and history - Yahoo Finance Singapore
Biogen Inc. (BIIBCL.SN) interactive stock chart - Yahoo Finance UK
Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN
BIIB (Biogen) 3-Year Revenue Growth Rate : -1.20% (As of Dec. 2025) - GuruFocus
Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story - Yahoo Finance Singapore
Stifel Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $214 - Moomoo
15,051 Shares in Biogen Inc. $BIIB Bought by Element Squared LLC - MarketBeat
Biogen (NASDAQ: BIIB) plans tender offer to acquire Apellis (APLS); materials pending - Stock Titan
Biogen (BIIB) CAO Sean Godbout nets shares from RSU vesting and tax withholding - stocktitan.net
Biogen to acquire Apellis in $5.6 billion deal - Ophthalmology Times
Biogen Inc stock: Plunges to $177.34 – What it means for you - AD HOC NEWS
Rx Rundown: Eli Lilly, Blackstone, Biogen and more - Medical Marketing and Media
Nisa Investment Advisors LLC Sells 9,121 Shares of Biogen Inc. $BIIB - MarketBeat
Biogen Inc. stock underperforms Thursday when compared to competitors - MSN
Weekly Buzz: SPRY Gains FDA Nod; EU Expands Kerendia Label; LLY Acquires CNTA; BIIB Snaps Up APLS - RTTNews
Biogen Inc. (BIIB) Stock Forecasts - Yahoo Finance
APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5.6B Deal With Biogen - Stocktwits
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.02%
2.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):